These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drug samples are meant for advertising. Thawani V Issues Med Ethics; 2001; 9(3):91. PubMed ID: 16334483 [No Abstract] [Full Text] [Related]
3. Promoting and advertising therapeutic goods. Trade Practices Commission report on self-regulation. Moulds RF Med J Aust; 1992 Oct; 157(8):513-4. PubMed ID: 1479969 [No Abstract] [Full Text] [Related]
4. Ethical code of the pharmaceutical industry in Slovakia. (Excerpts). Med Etika Bioet; 2004; 11(3-4):11-22. PubMed ID: 16294449 [No Abstract] [Full Text] [Related]
5. Issues in bringing new drugs to the market. Ammann AJ Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171 [No Abstract] [Full Text] [Related]
6. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
7. [Physician and pharmaceutical industry. II. Postmarketing surveillance]. Egberts AC; Lenderink AW; ter Steege H Ned Tijdschr Geneeskd; 1992 Feb; 136(6):297-8. PubMed ID: 1741077 [No Abstract] [Full Text] [Related]
8. ["There are clear criteria for product surveillance studies"]. Throm S MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777 [No Abstract] [Full Text] [Related]
9. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Kesselheim AS; Fischer MA; Avorn J Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191 [TBL] [Abstract][Full Text] [Related]
10. Promotion of medicines. Massam D Lancet; 1989 Jun; 1(8650):1330. PubMed ID: 2566856 [No Abstract] [Full Text] [Related]
11. Industry reneges on postmarketing trial commitments. Bouchie A Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074 [No Abstract] [Full Text] [Related]
12. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
13. Blood dyscrasias and the pharmaceutical industry: screening surveillance and monitoring, and future drug development. Eur J Haematol Suppl; 1996; 60():128-9. PubMed ID: 8987256 [No Abstract] [Full Text] [Related]
14. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases. Shea LL; Hanson A; Guglielmetti TM; Levy K Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388 [No Abstract] [Full Text] [Related]
15. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product. Bamber MG BMJ; 1999 Mar; 318(7186):810, author reply 810-11. PubMed ID: 10082724 [No Abstract] [Full Text] [Related]
16. Mandatory post marketing studies. Somberg J Am J Ther; 2007; 14(4):321. PubMed ID: 17667203 [No Abstract] [Full Text] [Related]
17. [Drug surveillance within the pharmaceutical industry: present and future]. Soto J; Sacristán JA; Alsar MJ; Galende I Med Clin (Barc); 1996 May; 106(17):665-9. PubMed ID: 8691914 [No Abstract] [Full Text] [Related]
18. FDA asks LyphoMed to recall intravenous solution. Wagner M Mod Healthc; 1988 Jul; 18(31):5. PubMed ID: 10288204 [No Abstract] [Full Text] [Related]